AVM
FATE icon

Arch Venture Management’s Fate Therapeutics FATE Stock Holding History

Arch Venture Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-716,392
Closed -$11.1M – 6
2019
Q3 		$11.1M Sell
716,392
-256,798
-26% -$4.92M 12.18% 4
2019
Q2 		$19.8M Sell
973,190
-300,000
-24% -$5.41M 20.45% 3
2019
Q1 		$22.4M Sell
1,273,190
-800,000
-39% -$12.6M 21.6% 3
2018
Q4 		$26.6M Buy
+2,073,190
New +$28.9M 26.59% 2

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Arch Venture Management's FATE Position: Q4 2019 in Review

Arch Venture Management sold out of Fate Therapeutics (FATE) in Q4 2019, closing a stake of 716,392 shares — an estimated $11.1M sold.

Arch Venture Management first reported a position in FATE in Q4 2018 and held it in 4 quarters. The position peaked at $26.6M in Q4 2018. 147 funds tracked by Wall St. Rank hold FATE as of Q4 2019.

  • Arch Venture Management reported no remaining Fate Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Arch Venture Management sold 716,392 Fate Therapeutics shares in Q4 2019, an estimated $11.1M.
  • Arch Venture Management first reported a position in Fate Therapeutics in Q4 2018 and held it in 4 quarters.
  • Arch Venture Management's Fate Therapeutics position peaked at $26.6M in Q4 2018.
  • 147 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2019.

Based on Arch Venture Management's 13F filing for Q4 2019, filed 5 Feb 2020.